Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Journal of the American Medical Association (JAMA)

• Publication date

  2015-07-21

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/jama.2015.7996PMID 26197187
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [Pioglitazone and the risk of bladder cancer].

  2016cited by this paper
• Utilization of glucose, blood pressure, and lipid lowering medications among people with type II diabetes in the United States, 1999-2010.

  2014cited by this paper
• Thiazolidinediones and cancer: results of a meta-analysis of randomized clinical trials

  2014cited by this paper
• Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta‐analysis

  2014cited by this paper
• Observational follow‐up of the PROactive study: a 6‐year update

  2014cited by this paper
• Proteinuria testing among patients with diabetes mellitus is associated with bladder cancer diagnosis: potential for unmeasured confounding in studies of pioglitazone and bladder cancer

  2014cited by this paper
• Pioglitazone does not affect the risk of kidney cancer in patients with type 2 diabetes.

  2014cited by this paper
• Pioglitazone--do we really need it to manage type 2 diabetes?

  2013cited by this paper
• Comparing Pioglitazone to Insulin with Respect to Cancer, Cardiovascular and Bone Fracture Endpoints, Using Propensity Score Weights

  2013cited by this paper
• Pioglitazone does not affect the risk of ovarian cancer: analysis of a nationwide reimbursement database in Taiwan.

  2013cited by this paper
• Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis.

  2013cited by this paper
• Panel recommends easing restrictions on rosiglitazone despite concerns about cardiovascular safety.

  2013cited by this paper
• Actos, slings, finasteride, and the vaccine compensation solution.

  2013cited by this paper
• Re: Radical Prostatectomy Versus Observation for Localized Prostate Cancer

  2013cited by this paper
• Antidiabetes drugs correlate with decreased risk of lung cancer: a population-based observation in Taiwan.

  2012cited by this paper
• Thiazolidinedione use and cancer incidence in type 2 diabetes: a systematic review and meta-analysis.

  2012cited by this paper
• Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus

  2012cited by this paper
• Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study

  2012cited by this paper
• Metformin and the Risk of Cancer

  2012cited by this paper
• Radical prostatectomy versus observation for localized prostate cancer.

  2012cited by this paper
• Pioglitazone and the risk of bladder cancer

  2012cited by this paper
• Balancing the risks and benefits for pioglitazone in type 2 diabetes.

  2012cited by this paper
• Diabetes drug may be associated with increase in risk of bladder cancer.

  2011cited by this paper
• Cohort Study of Pioglitazone and Cancer Incidence in Patients With Diabetes

  2011cited by this paper
• Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone

  2011cited by this paper
• Long-Term Metformin Use Is Associated With Decreased Risk of Breast Cancer

  2010cited by this paper
• Regulatory action on rosiglitazone by the U.S. Food and Drug Administration.

  2010cited by this paper
• Rat Urinary Bladder Carcinogenesis by Dual-Acting PPARα + γ Agonists

  2009cited by this paper
• Antidiabetic therapies affect risk of pancreatic cancer.

  2009cited by this paper
• Risk of cancer among hairdressers and related workers: a meta-analysis.

  2009cited by this paper
• Cancer incidence among patients treated with antidiabetic pharmacotherapy

  2008cited by this paper
• Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes.

  2007cited by this paper
• Cancer risks in thiazolidinedione users compared to other anti‐diabetic agents

  2007cited by this paper
• A Case-Control Study

  2006cited by this paper
• Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.

  2005cited by this paper
• Kaiser Permanente Medical Care Program: Division of Research, Northern California, and Center for Health Research, Northwest Division

  2002cited by this paper
• Infant Pneumococcal Vaccine

  2000cited by this paper
• Bacterial Contamination Alert

  2000cited by this paper
• A meta-analysis of painting exposure and cancer mortality.

  1998cited by this paper

• Metabolic dysregulation: Its role in diabetes mellitus and cancers.

  2026cites this paper
• Low-grade non-muscle-invasive bladder cancer: molecular landscape, treatment strategies and emerging therapies

  2025cites this paper
• Metabolic dysfunction-associated steatotic liver disease: Pathogenesis, model and treatment (Review)

  2025cites this paper
• Modulating the PPARγ pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancer

  2025cites this paper
• Design, synthesis, and antidiabetic evaluation of thiazolidinedione derivatives as potent PPAR-γ Agonists: Insights from molecular docking, MD simulations and invitro studies

  2025cites this paper
• Pioglitazone Suppresses Urothelial Tumorigenesis In Vitro: A Potential Chemopreventive Agent

  2025cites this paper
• Safety of Alopecia Treatments in Patients with Breast Cancer and High-Risk Women: A Review

  2025cites this paper
• Pioglitazone as Add-On to Metformin and Dapagliflozin Yields Significant Enhancements in Glycemic Control in Poorly Controlled Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials

  2025cites this paper
• Safety Warnings on the Same Harmful Effects of Medicines: A Comparison of Four National Regulators

  2025influential citation
• Rethinking metformin in advanced endometrial cancer: Scientific humility, translational challenges, and the urgency for equity.

  2025cites this paper
• Anti-diabetic medications and cancer: links beyond glycemic and body weight control

  2025cites this paper
• The Many Facets of PPAR-γ Agonism in Obesity and Associated Comorbidities: Benefits, Risks, Challenges, and Future Directions

  2025cites this paper
• Role of anti-diabetic medications in the management of MASLD

  2025cites this paper
• Updated recommendations for the management of metabolic dysfunction-associated steatotic liver disease (MASLD) by the Latin American working group.

  2025cites this paper
• Type 2 Diabetes Mellitus and bladder cancer: A narrative review on associated signaling pathways.

  2025cites this paper
• PPAR-γ activation by pioglitazone inhibits microglia-mediated neuroinflammation and alleviates disease in neuromyelitis optica spectrum disorders

  2025cites this paper
• 2,4-Thiazolidinedione in Treating Diabetes: A Comprehensive Overview - History, Chemistry, Advancements, Challenges and Future Perspectives

  2025cites this paper
• Exploration of Glitazone/Thiazolidinedione Derivatives: Molecular Design and Therapeutic Potential

  2025cites this paper
• Cancer biology in diabetes update: Focusing on antidiabetic drugs

  2024cites this paper
• PPAR-γ agonist pioglitazone and the risks of malignancy among type2 diabetes mellitus patients

  2024cites this paper
• Beyond the Liver: A Comprehensive Review of Strategies to Prevent Hepatocellular Carcinoma

  2024cites this paper
• Association between pioglitazone use and bladder cancer: A systematic review

  2024cites this paper
• Frontal Fibrosing Alopecia: An Update

  2024cites this paper
• A consensus statement from the Japan Diabetes Society (JDS): a proposed algorithm for pharmacotherapy in people with type 2 diabetes—2nd Edition (English version)

  2024cites this paper
• Associations between Diabetes Mellitus and Selected Cancers

  2024influential citation
• Hypoglycemic Agents Increase Regulatory Factor X1 to Inhibit Cancer Cell Behaviour in Human Glioblastoma Cells

  2024cites this paper
• Causal relationship between type 2 diabetes and common respiratory system diseases: a two-sample Mendelian randomization analysis

  2024cites this paper
• In Silico Analysis of 2,4-Thiazolidinedione Derivatives as Potential Insulin Sensitizers for the Treatment of Diabetes Mellitus

  2024cites this paper
• Reassessment of pioglitazone and bladder cancer based on FAERS database

  2024cites this paper
• Pharmacological Approaches to Nonalcoholic Fatty Liver Disease: Current and Future Therapies

  2024cites this paper
• Metabolic dysfunction-associated steatotic liver disease and urinary system cancers: Mere coincidence or reason for concern?

  2024cites this paper
• Genetic association of type 2 diabetes and antidiabetic drug target with skin cancer

  2024cites this paper
• Anti-Diabetic Therapies and Cancer: From Bench to Bedside

  2024cites this paper
• A consensus statement from the Japan Diabetes Society: A proposed algorithm for pharmacotherapy in people with type 2 diabetes – 2nd edition (English version)

  2024cites this paper
• Effect of combination pioglitazone with sodium‐glucose cotransporter‐2 inhibitors or glucagon‐like peptide‐1 receptor agonists on outcomes in type 2 diabetes: A systematic review, meta‐analysis, and real‐world study from an international federated database

  2024cites this paper
• Avoiding and managing the side effects of type 2 diabetes treatments

  2023cites this paper
• An update on diagnosis and therapeutics for type-2 diabetes mellitus

  2023cites this paper
• The association between pioglitazone consumption and incidence of bladder cancer in type II diabetic patients: a systematic review and meta-analysis of observational studies

  2023cites this paper
• Effects of half-dose spiomet treatment in girls with early puberty and accelerated bone maturation: a multicenter, randomized, placebo-controlled study protocol

  2023cites this paper
• Hypoglycemic effects of dendrobium officinale leaves

  2023cites this paper
• [Rediscovery of pioglitazone].

  2023cites this paper
• Obesity and Main Urologic Cancers: Current Systematic Evidence, Novel Biological Mechanisms, Perspectives and Challenges.

  2023cites this paper
• Thiazolidinedione as a Promising Medicinal Scaffold for the Treatment of Type 2 Diabetes.

  2023cites this paper
• Protective Effect of Sea Buckthorn (Hipphophae Rhamnoides) Extract on Liver Injury Induced by High-Fat Diet in Mice.

  2023cites this paper
• The Role of Real-World Evidence in Treatment Decision-Making, Regulatory Assessment, and Understanding the Perspectives of People with Type 2 Diabetes: Examples with Gliclazide MR

  2023cites this paper
• Neuroinflammation in fetal alcohol spectrum disorders and related novel therapeutic approaches.

  2023cites this paper
• Rosiglitazone has a null association with the risk of prostate cancer in type 2 diabetes patients

  2023cites this paper
• Impact of Fixed Combination of Metformin and Pioglitazone on Insulin Resistance of Patients with Type 2 Diabetes: Results of a Randomized Open-Label Study

  2023cites this paper
• Hypoglycemic agents and incidence of pancreatic cancer in diabetic patients: a meta-analysis

  2023influential citation
• In praise of pioglitazone: An economically efficacious therapy for type 2 diabetes and other manifestations of the metabolic syndrome

  2023cites this paper
• Diabète et cancer

  2022cites this paper
• The crosstalk between insulin resistance and nonalcoholic fatty liver disease/metabolic dysfunction-associated fatty liver disease: a culprit or a consequence?

  2022cites this paper
• Bladder cancer with pioglitazone: A case-control study.

  2022cites this paper
• Reversible hair loss in a patient with cicatricial alopecia: A case of regrowth associated with pioglitazone use

  2022cites this paper
• American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update.

  2022cites this paper
• Letter to the Editor from Han and Xu "Association between DPP4 inhibitor use and the incidence of cirrhosis, ESRD, and some cancers in patients with diabetes".

  2022cites this paper
• Pioglitazone and Prostate Cancer Risk in Taiwanese Male Patients with Type 2 Diabetes: A Retrospective Cohort Study

  2022cites this paper
• Pathophysiology, phenotypes and management of type 2 diabetes mellitus in Indian and Chinese populations

  2022cites this paper
• Pioglitazone, Bladder Cancer and the Presumption of Innocence.

  2022cites this paper
• Metabolic syndrome and bladder cancer.

  2022cites this paper
• Pioglitazone and breast cancer risk in female patients with type 2 diabetes mellitus: a retrospective cohort analysis

  2022influential citation
• Clinical practice guidelines for management of hyperglycaemia in adults with diabetic kidney disease

  2022cites this paper
• A Narrative Review on Axonal Neuroprotection in Multiple Sclerosis

  2022cites this paper
• Tratamiento de la diabetes mellitus tipo 2 en personas de edad avanzada o frágiles. Actualización 2022 del documento de consenso 2018 «Tratamiento de la diabetes mellitus tipo 2 en el paciente anciano»

  2022cites this paper
• Extra-Glycemic Effects of Anti-Diabetic Medications: Two Birds with One Stone?

  2022cites this paper
• SUMOylation Pattern Predicts Prognosis and Indicates Tumor Microenvironment Infiltration Characterization in Bladder Cancer

  2022cites this paper
• Diabetes and Pancreatic Cancer—A Dangerous Liaison Relying on Carbonyl Stress

  2021cites this paper
• Increased DNA strand breaks and neoplastic transformation in human bladder cells treated with pioglitazone

  2021cites this paper
• Diabetes in People with HIV

  2021cites this paper
• Fatty Liver - Current and Future Treatment: A Narrative Review

  2021cites this paper
• Personalizing Diabetes Management in Liver Transplant Recipients: The New Era for Optimizing Risk Management

  2021cites this paper
• Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)

  2021cites this paper
• Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO).

  2021cites this paper
• CUA GUIDELINE Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer – Full-text

  2021cites this paper
• Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO).

  2021cites this paper
• Environmental and Genetic Factors Contributing to Bladder Carcinogenesis

  2021cites this paper
• Personalized approach for type 2 diabetes pharmacotherapy: where are we and where do we need to be?

  2021cites this paper
• Diabetes and pancreatic cancer: Exploring the two-way traffic

  2021cites this paper
• Reduced alcohol use in patients prescribed pioglitazone.

  2021cites this paper
• Cardioprotective Effects of Pioglitazone in Type 2 Diabetes

  2021influential citation
• Recent Perspective on Thiazolidinedione

  2021cites this paper
• Treatment of type 2 diabetes mellitus and risk of pancreatic cancer.

  2021cites this paper
• Цукровий діабет та онкологічні захворювання

  2021cites this paper
• Impact of statin treatment on non-invasive tests based prediction of fibrosis

  2021cites this paper
• The Risk of Bladder Cancer in Type 2 Diabetes Mellitus with Combination Therapy of SGLT-2 Inhibitors and Pioglitazone

  2021cites this paper
• CUAJ – CUA Guideline Bhindi et al Guideline: NMIBC management

  2021cites this paper
• New Aspects of Diabetes Research and Therapeutic Development

  2021cites this paper
• Canadian Urological Association guideline on the management of non-muscle invasive bladder cancer.

  2021cites this paper
• Diabetes and Frailty: An Expert Consensus Statement on the Management of Older Adults with Type 2 Diabetes

  2021cites this paper
• Ranitidine Use and Gastric Cancer Among Persons with Helicobacter pylori

  2021cites this paper
• Gestione del paziente con diabete e cancro: è tempo di un approccio dedicato/integrato

  2021cites this paper
• The Influence of Anti-Diabetic Drugs on Prostate Cancer

  2021cites this paper
• An overview of alogliptin + pioglitazone for the treatment of type 2 diabetes

  2021cites this paper
• RECENT PATTERNS OF BLADDER CANCER INCIDENCE AND MORTALITY: A GLOBAL OVERVIEW

  2020cites this paper
• Type 2 diabetes and cancer: problems and suggestions for best patient management

  2020cites this paper
• Iraqi Experts Consensus on the Management of Type 2 Diabetes/Prediabetes in Adults

  2020cites this paper
• Effect of diabetes mellitus and glycemic control on the prognosis of non-muscle invasive bladder cancer: a retrospective study

  2020cites this paper
• Do Case-Control Studies Always Estimate Odds Ratios?

  2020cites this paper
• Recent advances in non-invasive diagnosis and medical management of non-alcoholic fatty liver disease in adult

  2020cites this paper
• Review of Associations Between Type 2 Diabetes and Cancer

  2020cites this paper